Induction of DNA fragmentation, chromosome aberrations and micronuclei by cisplatin in rat bone-marrow cells: Protective effect of recombinant human erythropoietin

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 747, Issue 2, 2012, Pages 202-206

  Rjiba Touati, Karima ^a   Ayed Boussema, Imen ^a   Skhiri, Habib ^b   Belarbia, Anis ^c   Zellema, Dorsaf ^c   Achour, Abdelatif ^c   Bacha, Hassen ^a  

^a Faculty of Dentistry   (Tunisia)

^b FATTOUMA BOURGUIBA UNIVERSITY HOSPITAL   (Tunisia)

^c University Hospital of Sahloul   (Tunisia)

Author keywords

Chromosome aberrations; Cisplatin; DNA fragmentation; Micronucleus; RhEPO

Indexed keywords

CISPLATIN; RECOMBINANT ERYTHROPOIETIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELL PROTECTION; CHROMOSOME ABERRATION; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA FRAGMENTATION; GENOTOXICITY; MALE; MICRONUCLEUS; MICRONUCLEUS TEST; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; CHROMOSOME ABERRATIONS; CISPLATIN; DNA DAMAGE; DNA FRAGMENTATION; ERYTHROPOIETIN; HUMANS; MALE; MICRONUCLEUS TESTS; MUTAGENS; PROTECTIVE AGENTS; RATS; RATS, WISTAR; RECOMBINANT PROTEINS;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 84863735204     PISSN: 13835718     EISSN: 18793592     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2012.05.011     Document Type: Article

References (46)

1. Prasad S.B., Giri A. Antitumor effect of cisplatin against murine ascites Dalton's lymphoma. Indian J. Exp. Biol. 1994, 32:57-62.
2. Taquchi T., Nazneen A., Abid M.R., Razzaque M.S. Cisplatin-associated nephrotoxicity and pathological events. Contrib. Nephrol. 2005, 148:107-121.
3. Tayem Y., Johnson T.R., Mann B.E., Green C.J., Motterlini R. Protection against cisplatin-induced nephrotoxicity by a carbon monoxide-releasing molecule. Am. J. Physiol. Renal Physiol. 2006, 290:789-794.
4. Timmer-Bosscha H., Mulder N.H., de Vries E.G.E. Modulation of cis-diammine-dichloroplatinum II resistance. Br. J. Cancer 1992, 66:227-238.
5. Kliesh U., Adler I.D. Micronucleus test in bone marrow of mice treated with 1-nitropropane, 2-nitropropane and cisplatin. Mutat. Res. 1987, 192:181-184.
6. Osanto S., Thijssen J.C.P., Woldering V.M., van Rijn J.L.S., Natarajan A.T., Tates A.D. Increased frequency of chromosomal damage in peripheral blood lymphocytes up to nine years following curative chemotherapy of patients with testicular carcinoma. Environ. Mol. Mutagen. 1991, 17:71-78.
7. Anirudha G., Khynriam D., Prasad S.B. Vitamin C mediated protection on cisplatin induced mutagenicity in mice. Mutat. Res. 1998, 421:139-148.
8. Tohamy A.A., El-Ghor A.A., El-Nahas S.M., Noshy M.M. Beta-glucan inhibits the genotoxicity of cyclophosphamide, adriamycin and cisplatin. Mutat. Res. 2003, 541:45-53.
9. Chirino Y.I., Hernandez-Panto R., Pedraza-Chaverri J. Peroxynitrite decomposition catalyst ameliorates renal damage and protein nitration in cisplatin-induced nephrotoxicity in rats. BMC Pharmacol. 2004, 4:20-29.
10. Overbeck T.L., Knight J.M., Beck D.J. A comparison of the genotoxic effects of carboplatin and cisplatin in Escherichia coli. Mutat. Res. 1996, 362:249-259.
11. Cross H.J., Tilby M., Chipman J.K., Ferry D.R., Gescher A. Effect of quercetin on the genotoxic potential of cisplatin. Int. J. Cancer 1996, 66:404-408.
12. Zwelling L.A., Bradley M.O., Sharkey N.A., Anderson T., Kohn K.W. Mutagenicity, cytotoxicity and DNA crosslinking in V79 Chinese hamster cells treated with cis- and trans-Pt II.diamminedichloride. Mutat. Res. 1979, 67:271-280.
13. Pillaire M.J., Margot A., Villani G., Sarasin A., Defais M., Gentil A. Mutagenesis in monkey cells of a vector containing a single d_GPG. cis-diamminedichloroplatinum II. Adduct placed on codon 13 of the human H-ras proto-oncogene. Nucleic Acids Res. 1994, 22:2519-2524.
14. Kempf S.R., Ivankovic S. Carcinogenic effect of cisplatin cis-diamminedichloroplatinum-II, CDDP. in BD IX rats. J. Cancer Res. Clin. Oncol. 1986, 111:133-136.
15. Greene M.H. Is cisplatin a human carcinogen?. J. Natl. Cancer Inst. 1992, 84:306-312.
16. Silva C.R., Greggi Antunes L.M., deP Bianchi M. Antioxidant action of bixin against cisplatin-induced chromosome aberrations and lipid peroxidation in rats. Pharmacol. Res. 2001, 43:561-566.
17. Sendao M.C., Behling E.B., dos Santos R.A., Antunes L.M.G., Bianchi M.L.P. Comparative effects of acute and subacute lycopene administration on chromosomal aberrations induced by cisplatin in male rats. Food Chem. Toxicol. 2006, 44:1334-1339.
18. Li F., Chong Z.Z., Maiese K. Erythropoietin on a tightrope: balancing neuronal and vascular protection between intrinsic and extrinsic pathways. Neurosignals 2004, 13:265-289.
19. Nemoto T., Yokota N., Keane W.F., Rabb H. Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure. Kidney Int. 2001, 59:246-251.
20. Rossert J., Eckardt K.U. Erythropoietin receptors: their role beyond eythropoiesis. Nephrol. Dial. Transplant. 2005, 20:1025-1028.
21. Hodges V.M., Rainey S., Lappin T.R., Maxwell A.P. Pathophysiology of anemia and erythrocytosis. Crit. Rev. Oncol. Hematol. 2007, 64:139-158.
22. Weiss M.J. New insights into erythropoietin and epoetin alfa: mechanisms of action, target tissues and clinical applications. Oncologist 2003, 8:18-29.
23. Csete M., Rodriguez L., Wilcox M., Chadalavada S. Erythropoietin receptor is expressed on adult rat dopaminergic neurons and erythropoietin is neurotrophic in cultured dopaminergic neuroblasts. Neurosci. Lett. 2004, 359:124-126.
24. Chatterjee P.K. Pleiotropic renal actions of erythropoietin. Lancet 2005, 365:1890-1892.
25. Sun Y., Zhou C., Polk P., Nanda A., Zhang J.H. Mechanisms of erythropoietin-induced brain protection in neonatal hypoxia-ischemia rat model. J. Cereb. Blood Flow Metab. 2004, 24:259-270.
26. Sharples E.J., Yaqoob M.M. Erythropoietin in experimental acute renal failure. Nephron Exp. Nephrol. 2006, 104:83-88.
27. Fenech M. The cytokinesis-block micronucleus technique: a detailed description of the method and its application to genotoxicity studies in human postulations. Mutat. Res. 1993, 285:35-44.
28. Kirsch-Volders M., El Hajaji A., Cundari E., Van Hummelen P. The in vitro micronucleus test: a multi-endpoint assay to detect simultaneously mitotic delay, apoptosis, chromosome breakage, chromosome loss and non-disjunction. Mutat. Res. 1997, 392:19-30.
29. Hayashi M., Sofuni T., Ishidate M. An application of Acridine Orange fluorescent staining to the micronucleus test. Mutat. Res. 1983, 120:241-247.
30. Yosida T.H., Amano K. Autosomal polymorphism in labora tory bred and wild Norway rats, Rattus norvegicus, found in Misima. Chromosoma 1965, 16:658-667.
31. Evans E.P., Breckon G., Ford C.E. An air drying method for meiotic preparation from mammalian testes. Cytogenetics 1960, 3:613-616.
32. Singh N.P., McCoy M.T., Tice R.R., Schneider E.L. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell Res. 1988, 175:184-191.
33. Collins A.R., Dusinska M., Gedik C.M., Stetina R. Oxidative damage to DNA: do we have a reliable biomarker?. Environ. Health Perspect. 1996, 104:465-469.
34. Cruel M., Schellens J.H.M., Beijnen J.H., Maliepaard M. Cisplatin resistance and DNA repair. Cancer Treat. Rev. 1997, 23:341-366.
35. Rosenberg B. Fundamental studies with cisplatin. Cancer 1985, 55:2303-2316.
36. Krishnaswamy G., Dewey W.C. Cisplatin induced cell killing and chromosomal aberrations in CHO cells treated during G1 or S phase. Mutat. Res. 1993, 293:161-172.
37. Antunes L.M.G., Araujo M.C.P., Darin J.D.C., Bianchi M.L.P. Effects of the antioxidants curcumin and vitamin C on cisplatin-induced clastogenesis in Wistar rat bone marrow cells. Mutat. Res. 2000, 465:131-137.
38. Mora L.O., Antunes L.M.G., Francescato H.D.C., Bianchi M.L.P. The effects of oral glutamine on cisplatin-induced genotoxicity in Wistar rat bone marrow cells. Mutat. Res. 2002, 518:65-70.
39. Simon F., Scheuerle A., Calzia E., Bassi G., Oter S., Duy C.N., Kick J., Brückner U.B., Radermacher P., Schelzig H. Erythropoietin during porcine aortic balloon occlusion-induced ischemia/reperfusion injury. Crit. Care Med. 2008, 36:2143-2150.
40. Sharples E.J., Patel N., Brown P., Stewart K., Mota-Philipe H., Sheaff M., Kieswich J., Allen D., Harwood S., Raftery M., Thiemermann C., Yaqoob M.M. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia reperfusion. J. Am. Soc. Nephrol. 2004, 15:2115-2124.
41. Jamieson E.R., Lippard S.J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev. 1999, 99:2467-2498.
42. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
43. Edelweiss M.I., Trachtenberg A., Pinheiro E.X., Da-Silva J., Riegel M., Lizardo-Daudt H.M., Mattevi M.S. Clastogenic effect of cisplatin on Wistar rat bone marrow cells. Braz. J. Med. Biol. Res. 1995, 28:679-683.
44. Tice R.R., Agurell E., Anderson D., Burlinson B., Hartmann A., Kobayashi H., Miyamae Y., Rojas E., Ryu J.C., Sasaki Y.F. Single cell gel/Comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ. Mol. Mutagen. 2000, 35:206-221.
45. Sasaki Y.F., Sekihashi K., Izumiyama F., Nishidate E., Saga A., Ishida K., Tsuda S. The Comet assay with multiple mouse organs: comparison of Comet assay results and carcinogenicity with 208 chemicals selected from the IARC monographs and US NTP Carcinogenicity Database. Crit. Rev. Toxicol. 2000, 30:629-799.
46. Hartmann A., Agurell E., Beevers C., Brendler-Schwaab S., Burlinson B., Clay P., Collins A., Smith A., Speit G., Thybaud V., Tice R.R. Recommendations for conducting the in vivo alkaline Comet assay. Mutagenesis 2003, 18:45-51.